Pathological response to neoadjuvant therapy with chemotherapy vs chemoradiotherapy in stage III NSCLC-contribution of IASLC recommendations.
Muñoz-Guglielmetti D, Sanchez-Lorente D, Reyes R, Martinez D, Lucena C, Boada M, Paredes P, Parera-Roig M, Vollmer I, Mases J, Martin-Deleon R, Castillo S, Benegas M, Muñoz S, Mayoral M, Cases C, Mollà M, Casas F.
Muñoz-Guglielmetti D, et al. Among authors: vollmer i.
World J Clin Oncol. 2021 Nov 24;12(11):1047-1063. doi: 10.5306/wjco.v12.i11.1047.
World J Clin Oncol. 2021.
PMID: 34909399
Free PMC article.